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Purpose
The vacuum-assisted breast biopsy (VABB) is a minimally invasive method for verifying unclear findings of the breast. For the histopathology, the B-classification has become established standard. B3 lesions (benign lesions with unclear malign potential) are a particular challenge for the further approach, as so far there are no binding recommendations regarding the further procedure.
Our study objective was to analyse all B3 lesions, diagnosed at VABB and captured in the central MIBB database
Methods and Materials
All 9152 stereotactically, sonographically or MRI-guided vacuum-assisted breast biopsies performed inSwitzerlandbetween 2009 and 2011, captured in a central database, were examined for the frequency of histolopathological B3 lesions. The B3 lesions were correlated with the imaging and analysed as well as compared with a subsequent surgical follow-up resection, if performed.
Results
Of the 9152 analysed biopsies, 1532 (17%) were B3 lesions (Fig.1) . Of those, 424 (18%) were ADH, 374 (25%) papillary lesions, 335 (23%) FEA, 245 (16%) LN and 113 (8%) radial scars.
Microcalcifications were present in 346 (82%) of ADH lesions, 135 (36%) of papillary lesions, 249 (88%) of FEA, 178 (73%) of lobular neoplasia and 72 (63%) of radial scars (Fig.2 ).
In 75% (1147/1532) of all biopsies with a B3 diagnosis a clip was inserted (Fig 3) . From the total number of all B3 lesions, in 48% (489/1017) of the cases the findings could be removed completely during the biopsy, in 51% (519/1017) of the cases partially (Fig.4) .
In 38% (521/1491) of all B3 lesions a surgical follow-up resection was performed (Fig.5) . For ADH the rate of malignancies after surgical follow-up resection was 26% (69/266), for lobular neoplasia 26% (24/91), for FEA 18% (15/82), for radial scar 11% (2/18) and for papillary lesion 3% (2/64). The rate of malignancies in the definitive histology for all B3 lesions was 21% (112/521).
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Conclusion
With 17% of all analysed biopsies, the B3 rate was high. The rate of malignant findings after a follow-up surgical excision is 21% for all B3 lesions; it was highest for ADH and LH with 26% each, followed by FEA with 18%. These data are intended to serve as a basis for recommendations by the Swiss MIBB group regarding the further procedure after a B3 lesion has been diagnosed in the VABB. 
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